Stock CENTRALPHL CENTRAL PHARMACEUTICALS LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Central Pharmaceuticals Ltd.

Equities

CENTRALPHL

BD0487CPL007

End-of-day quote Dhaka S.E.
Other stock markets
 06:00:00 2024-05-22 pm EDT 		5-day change 1st Jan Change
18.2 BDT -2.67% Intraday chart for Central Pharmaceuticals Ltd. -10.34% -9.90%
Mar. 11 Central Pharmaceuticals Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
2023 Central Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended June 30, 2023 CI

Valuation

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Capitalization 1 1,734 1,509 1,593 1,581 1,569 1,486
Enterprise Value (EV) 1 1,933 1,709 1,815 1,830 1,836 1,753
P/E ratio 28.5 x 26.4 x -1.44 x -184 x -23 x -33.8 x
Yield - 0.79% - - - -
Capitalization / Revenue 5.43 x 4.91 x 11.4 x 10.7 x 60.4 x 50.7 x
EV / Revenue 6.05 x 5.56 x 13 x 12.4 x 70.6 x 59.8 x
EV / EBITDA 14.1 x 12.3 x -1.71 x 46.3 x -77.8 x -83 x
EV / FCF -270 x 25.1 x 6.53 x -92.6 x 224 x 98.5 x
FCF Yield -0.37% 3.98% 15.3% -1.08% 0.45% 1.02%
Price to Book 0.96 x 0.85 x 2.02 x 2.02 x 2.2 x 2.22 x
Nbr of stocks (in thousands) 119,801 119,801 119,801 119,801 119,801 119,801
Reference price 2 14.48 12.60 13.30 13.20 13.10 12.40
Announcement Date 11/27/18 8/29/19 12/27/20 1/12/22 11/3/22 12/28/23
1BDT in Million2BDT
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net sales 1 319.6 307.5 140.1 148.2 26 29.33
EBITDA 1 137.5 138.8 -1,064 39.56 -23.59 -21.11
EBIT 1 93.94 98.75 -1,100 6.684 -53.35 -47.86
Operating Margin 29.39% 32.12% -785.11% 4.51% -205.21% -163.18%
Earnings before Tax (EBT) 1 80.72 63.04 -1,110 -14.76 -70.82 -47.87
Net income 1 60.91 57.09 -1,107 -8.601 -68.25 -43.96
Net margin 19.06% 18.57% -790.2% -5.81% -262.51% -149.88%
EPS 2 0.5084 0.4766 -9.240 -0.0718 -0.5697 -0.3669
Free Cash Flow 1 -7.148 68.05 278.1 -19.77 8.19 17.79
FCF margin -2.24% 22.13% 198.5% -13.34% 31.5% 60.67%
FCF Conversion (EBITDA) - 49.02% - - - -
FCF Conversion (Net income) - 119.19% - - - -
Dividend per Share - 0.1000 - - - -
Announcement Date 11/27/18 8/29/19 12/27/20 1/12/22 11/3/22 12/28/23
1BDT in Million2BDT
Estimates

Balance Sheet Analysis

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net Debt 1 199 200 222 248 267 267
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 1.445 x 1.439 x -0.2088 x 6.278 x -11.31 x -12.66 x
Free Cash Flow 1 -7.15 68 278 -19.8 8.19 17.8
ROE (net income / shareholders' equity) 3.44% 3.19% -86.1% -1.09% -9.12% -6.35%
ROA (Net income/ Total Assets) 2.52% 2.55% -35.9% 0.31% -2.49% -2.32%
Assets 1 2,420 2,243 3,083 -2,801 2,739 1,895
Book Value Per Share 2 15.00 14.90 6.600 6.530 5.960 5.590
Cash Flow per Share 2 0.0600 0.0500 0.0300 0.0300 0.0100 0.0100
Capex 1 12.4 11.3 - 6.57 - -
Capex / Sales 3.87% 3.66% - 4.44% - -
Announcement Date 11/27/18 8/29/19 12/27/20 1/12/22 11/3/22 12/28/23
1BDT in Million2BDT
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

  1. Stock Market
  2. Equities
  3. CENTRALPHL Stock
  4. Financials Central Pharmaceuticals Ltd.